How the body's cannabinoid and opioid systems contribute to nicotine addiction | Research

The takeaway

A review examined how the endocannabinoid and opioid systems modulate nicotine reward, dependence, and relapse, suggesting cannabinoid or opioid antagonists could help treat tobacco addiction.

Read this if you are interested in the neuroscience of nicotine addiction and potential roles for cannabinoid-based treatments.

Cannabinoid and opioid antagonists showed preclinical promise for smoking cessation

What the researchers found

The review detailed how the endogenous cannabinoid and opioid systems interact with dopamine-driven reward pathways that underlie nicotine addiction. Both systems were found to play modulatory roles across multiple aspects of tobacco dependence.

The endocannabinoid system participated in nicotine's rewarding properties, the development of physical dependence, and relapse to nicotine-seeking behavior. Similarly, the opioid system contributed to nicotine reward processing.

Preclinical evidence supported the use of cannabinoid or opioid receptor antagonists as potential treatments for nicotine addiction, and early clinical trials showed promise.

Why it matters

Understanding how multiple neurotransmitter systems contribute to nicotine addiction could open new treatment pathways beyond traditional nicotine replacement therapy.

The numbers in context

The review synthesized findings across multiple preclinical and clinical studies but did not report pooled statistics.

How the study worked

This was a narrative review published in Current Drug Targets synthesizing behavioral and biochemical data on the roles of endocannabinoid and opioid systems in nicotine addiction, including both preclinical animal studies and early clinical trial data.

What this study cannot tell us

As a narrative review, the evidence was not systematically evaluated. The clinical trial data available at the time was limited, and the translation from animal models to human outcomes remained uncertain.

How to read the evidence

Narrative review synthesizing substantial preclinical evidence and early clinical data across the field.

When this study was published

Published in 2010. Research on cannabinoid-based smoking cessation approaches has continued since.

The bigger picture

This research highlighted that addiction involves complex interactions among multiple neurotransmitter systems, suggesting that targeting the endocannabinoid or opioid system could provide novel smoking cessation strategies.

Questions still open

Would cannabinoid antagonists prove effective and tolerable as smoking cessation aids in large clinical trials? How do individual genetic differences in these systems affect treatment response?

Common questions

Could cannabinoid drugs help people quit smoking?

Preclinical evidence suggested cannabinoid receptor antagonists could reduce nicotine reward and relapse. Clinical translation was still in early stages at the time of this review.

What is the connection between the cannabinoid system and nicotine?

The endocannabinoid system modulates the dopamine reward pathways involved in nicotine addiction, influencing drug reward, physical dependence, and relapse behavior.

Read the original research

Endogenous cannabinoid and opioid systems and their role in nicotine addiction.

Current drug targets, 11(4), 440-9

View on PubMed ↗

Citation

Maldonado, Rafael; Berrendero, Fernando. (2010). Endogenous cannabinoid and opioid systems and their role in nicotine addiction.. Current drug targets, 11(4), 440-9.